美国纽约大学2016- 2018年为军方野外行动中，对三种抗疟疾药物：氯喹，马拉隆和强力霉素对狂犬病疫苗抗体的抑制作用，进行了试验研究，试验结果发表于： 2020 Mar。
结论是：与马拉隆和强力霉素相比，唯有氯喹对疫苗抗体抑制作用明显，达到可以接受的水平。
这些研究开始于Covid疫情之前，和左右，政治，药价没有任何关系。
试验的详细情况：
Healthy adults aged 18 to 60 were recruited from 11-Nov-2016 to 07-Jun-2018 in and around the study site in Syracuse, New York
https://clinicaltrials.gov/ct2/show/results/NCT02564471?view=results
发表的试验结果：
Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen
Timothy P Endy 1 2,
Paul B Keiser 3,
Don Cibula 4,
Mark Abbott 1,
Lisa Ware 1,
Stephen J Thomas 1,
Mark E Polhemus 1
Affiliations expand
PMID: 31743394
DOI:
10.1093/infdis/jiz558
Abstract
Background: Chloroquine can impair the immune responses to intradermal rabies vaccination. Current guidelines recommend an extra intramuscular dose be given for postexposure prophylaxis in previously unvaccinated persons taking any antimalarial drug.
Methods: We conducted a randomized, open-label, single-site study in 103 previously unvaccinated healthy adults age ≥18 to ≤60 years old to evaluate the effects of chloroquine, atovaquone/proguanil (Malarone), and doxycycline on the antibody response to a purified chick embryo cell vaccine, given on a postexposure prophylaxis schedule. All treatment groups received antimalarials 14 days prior to and during vaccination.
Results: All subjects achieved accepted neutralizing antibody titers of ≥0.5 IU/mL following the second rabies vaccination dose and maintained this protection through the duration of the study. We observed a reduction in rabies antibody geometric mean titer in the chloroquine versus control groups 28 days after vaccination: 2.3 versus 6.87 IU/mL, respectively (P < .001, t test). A significant difference was not observed for those taking Malarone or doxycycline.
Conclusions: We conclude that there is no reduction of rabies antibody response in subjects taking Malarone or doxycycline,
but a significant reduction in those taking chloroquine; however, accepted antibody levels were achieved for all 3 antimalarials.
Clinical trials registration: NCT02564471.
Keywords: antimalarial drugs; prophylaxis; rabies; vaccination.
NCT02564471.
pubmed.ncbi.nlm.nih.gov
www.ctvnews.ca
